Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost of poor adherence to anti-hypertensive therapy in five European countries.
Mennini FS, Marcellusi A, von der Schulenburg JM, Gray A, Levy P, Sciattella P, Soro M, Staffiero G, Zeidler J, Maggioni A, Schmieder RE. Mennini FS, et al. Among authors: von der schulenburg jm. Eur J Health Econ. 2015 Jan;16(1):65-72. doi: 10.1007/s10198-013-0554-4. Epub 2014 Jan 5. Eur J Health Econ. 2015. PMID: 24390212
Real-world evidence for coverage determination of treatments for rare diseases.
Dayer VW, Drummond MF, Dabbous O, Toumi M, Neumann P, Tunis S, Teich N, Saleh S, Persson U, von der Schulenburg JG, Malone DC, Salimullah T, Sullivan SD. Dayer VW, et al. Orphanet J Rare Dis. 2024 Feb 7;19(1):47. doi: 10.1186/s13023-024-03041-z. Orphanet J Rare Dis. 2024. PMID: 38326894 Free PMC article.
Note from the editor, January 2021.
von der Schulenburg JG, Braun S, Zeidler J. von der Schulenburg JG, et al. Health Econ Rev. 2021 Mar 27;11(1):12. doi: 10.1186/s13561-021-00311-5. Health Econ Rev. 2021. PMID: 33772664 Free PMC article. No abstract available.
Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany.
Wahler S, Müller A, Koll C, Seyed-Abbaszadeh P, Von Der Schulenburg JM. Wahler S, et al. Among authors: von der schulenburg jm. J Mark Access Health Policy. 2020 Dec 28;9(1):1861804. doi: 10.1080/20016689.2020.1861804. J Mark Access Health Policy. 2020. PMID: 33456727 Free PMC article.
Evaluation of two family-based intervention programs for children affected by rare disease and their families - research network (CARE-FAM-NET): study protocol for a rater-blinded, randomized, controlled, multicenter trial in a 2x2 factorial design.
Boettcher J, Filter B, Denecke J, Hot A, Daubmann A, Zapf A, Wegscheider K, Zeidler J, von der Schulenburg JG, Bullinger M, Rassenhofer M, Schulte-Markwort M, Wiegand-Grefe S. Boettcher J, et al. BMC Fam Pract. 2020 Nov 20;21(1):239. doi: 10.1186/s12875-020-01312-9. BMC Fam Pract. 2020. PMID: 33218310 Free PMC article.
104 results